Trial: 202009139

Phase I Study with Dose Expansion of Acalabrutinib and Durvalumab (MEDI 4736) in Primary and Secondary Central Nervous System Lymphoma

Phase

I

Principal Investigator

Mehta-Shah, Neha

Disease Site

Brain and Nervous System; Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov